MedCrave
Step into the World of Research

Journal of Psychology & Clinical Psychiatry

Review article

Open Access

CrossMark

Beyond tapering: understanding the biological, social, and recovery challenges of mixed withdrawal from psychiatric medications and opioids

Abstract

The complexities surrounding the withdrawal and tapering of psychiatric medications, such as benzodiazepines, antidepressants, mood stabilizers, and antipsychotics, have garnered increased attention in recent years. However, existing discussions often oversimplify the multifaceted realities faced by individuals, particularly those with co-occurring substance use disorders, including opioid dependence. These individuals navigate a withdrawal experience shaped by a complex interplay of pharmacological, psychological, and sociocultural influences, which is frequently overlooked in the current discourse.

In this article, we utilize clinical case scenarios to delve into the lived experiences of individuals going through mixed withdrawal from psychiatric medications alongside opioids. These cases reveal the biological intricacies of poly-pharmacy and emphasize the significant role that social and cultural contexts play in shaping withdrawal experiences and interpretations. Furthermore, we highlight the importance of recovery-oriented frameworks that can provide essential support throughout the withdrawal process.

We contend that current clinical protocols often fail to address the nuanced and diverse needs of individuals facing this complex clinical situation. We advocate for a more integrative approach that prioritizes cultural competence, peer support, and personalized recovery strategies to remedy this. This article views mixed withdrawal within a broader contextual framework, urging a reexamination of withdrawal approaches to embrace a comprehensive understanding of the lived experiences that characterize tapering and healing.

Keywords: mixed withdrawal from opioids and psychiatric medications, contextual recovery: social and cultural factors, lived experience in withdrawal, integrated healing approaches, polypharmacy and tapering challenges

Volume 16 Issue 4 - 2025

Marcello Maviglia,[1] Norman J Cooeyate,[2] Donald Hume[3]

[1]Clinical Professor, Family and Community Medicine/ Core Faculty Member at CNAH (Center for Native American Health), University of New Mexico, USA
[2]Associate Director, Center for Native American Health - a Public Health Institute for Indigenous Knowledge and Development/Lecturer II, Department of Family & Community Medicine/University of New Mexico Health Sciences, USA
[3]Senior Peer Specialist, Presbyterian Health Care Services, USA

Correspondence: Marcello Maviglia, Clinical Professor, Family and Community Medicine/ Core Faculty Member at CNAH (Center for Native American Health)/ University of New Mexico, Albuquerque, USA, Tel 505-272-1855/ 1505620628

Received: June 09, 2025 | **Published:** July 21, 2025

Introduction

The co-prescription of opioids and psychiatric medications presents a complex clinical challenge for individuals experiencing both mental health and substance use disorders, as well as for their clinicians. These overlapping treatments often complicate care, especially during withdrawal, where symptoms may be misinterpreted or inadequately addressed. In the United States, a significant proportion of opioid prescriptions - estimated at over 50% - are issued to individuals with co-occurring mental health conditions.[1] Furthermore, individuals with severe mental illness are approximately 2.5 times more likely to receive opioid prescriptions for chronic pain compared to the general population, highlighting the need for integrated and personalized care strategies.[2]

In addition to the widespread use of Medication-Assisted Treatment (MAT) for opioid use disorder, which encompasses over 2.5 million individuals, many patients simultaneously receive psychiatric medications often without coordinated oversight.[3] Unfortunately, the abrupt discontinuation of either class of drugs is frequent, leading to withdrawal syndromes that are difficult to diagnose and manage. The overlapping symptoms associated with withdrawal from opioids and psychiatric medications can lead to misdiagnoses, inappropriate treatment interventions, and an increased risk of more complex relapse episodes or harmful consequences.[4]

Sociocultural factors complicate these clinical challenges even more. Cultural beliefs, ethnic identity, and community support systems play crucial roles in how individuals interpret and respond to withdrawal symptoms. The literature emphasizes the critical impact of community environments on the recovery and treatment of those affected by opioid use disorders (OUDs). Research suggests that medication-assisted treatment (MAT), while beneficial, often requires individuals to adopt new self-concepts and cultural narratives to enhance treatment responsiveness and outcomes.[5] This notion aligns with findings indicating that individuals who can re-frame their addiction narratives—transforming their identity from one associated with substance misuse to one aligned with recovery—exhibit better adherence to treatment and coping strategies during withdrawal.[5,6] Community perceptions of substance use and the stigma surrounding it can further complicate how individuals experience these physical symptoms during withdrawal. An ethno pharmacological perspective reveals that cultural framework influence symptom expression, treatment engagement, and adherence.[7]

The understanding of mental health can vary across cultures, which can affect community support systems and individual behaviors during withdrawal. Familial expectations can determine whether individuals seek help for withdrawal symptoms or attempt to self-medicate in ways that may not align with their health needs.[8]

Research indicates the necessity of fostering hope and community connections to facilitate recovery. Initiatives that harness community support and peer mentorship can significantly enhance recovery capital, assisting individuals in navigating the complexities of withdrawal and improving treatment engagement.[9] Such support structures are essential, especially when considering the aversive symptoms associated with opioid withdrawal and the potential for

relapse if individuals lack adequate social support.[10] By recognizing how cultural beliefs, stigma, and community relationships influence the withdrawal experience, clinicians can tailor their interventions to align with the social contexts of their patients, thereby enhancing treatment efficacy and improving outcomes.

Peer specialists - individuals with lived experience of mental health and substance use in recovery - provide a critical source of support. Their involvement can bridge the divide between clinical protocols and patient realities, fostering trust, cultural sensitivity, and recovery-oriented care. By validating patient experiences and advocating for tailored approaches, peer specialists assist in reframing withdrawal as both a biomedical event and a deep contextual process.

The withdrawal signs and symptoms from psychiatric medications, are frequently mistaken for relapse, resulting in unnecessary or intensified pharmacological interventions. This misinterpretation may contribute to the "kindling effect," wherein withdrawal symptoms become increasingly severe with each subsequent episode.[11]

The contributions of scholars and advocates such as Peter Breggin,[12] Mark Horowitz,[13] Joanna Moncrieff,[14] Will Hall,[15] Adele Framer,[16] John Read,[17] and Giovanni Fava[18] have been instrumental in reshaping our understanding of psychiatric medication withdrawal. Adele Framer has developed a respected framework for safe tapering and symptom management through her platform, SurvivingAntidepressants.org, providing scientific insights and guidance informed by lived experience.

This article builds on these contributions, presenting clinical cases that illustrate the complexities of mixed withdrawal. We advocate for developing evidence-based, culturally informed, and recovery-oriented clinical protocols through this lens. By examining specific case scenarios, we aim to offer practical strategies for clinicians supporting individuals through the challenging experience of mixed withdrawal.

The experience of Mr. M

To illustrate the layered complexity of mixed withdrawal states, we present the case of Mr. M - a 45-year-old man of mixed Asian and Native American heritage - who underwent concurrent withdrawal from methadone, a long-acting opioid agonist, and escitalopram, a selective serotonin reuptake inhibitor (SSRI). This case offers a grounded, real-world lens through which to examine the diagnostic and therapeutic challenges of poly-pharmacy withdrawal. We have obscured all personal information in accordance with ethical guidelines.

Withdrawal symptoms

Mr. M's clinical presentation is emblematic of the multifaceted nature of mixed withdrawal. Signs and symptoms consistent with opioid withdrawal were assessed using the Clinical Opiate Withdrawal Scale (COWS), a validated tool for evaluating opioid withdrawal.[19] The initial presentation included the following signs and symptoms:

(i) Elevated resting pulse rate

(ii) Increased sweating

(iii) Restlessness

(iv) Dilated pupils

(v) Significant bone or joint aches

(vi) Gastrointestinal distress (nausea, vomiting, diarrhea)

(vii) Severe anxiety and irritability

Simultaneously, symptoms indicative of SSRI withdrawal were evaluated using the Discriminatory Antidepressant Withdrawal Symptoms Scale (DAWSS), which captures hallmark features of antidepressant withdrawal.[4] Mr. M reported:

(i) Mood swings

(ii) Persistent depressive symptoms

(iii) Tingling sensations in the extremities

(iv) Electric shock-like sensations ("brain zaps")

(v) Dizziness

(vi) Akathisia (restlessness, uncontrollable urge to move).

(vii) Vertigo

While Mr. M had previously experienced opioid withdrawal, this episode was qualitatively different. The co-occurrence of neurological and affective symptoms—particularly the electric shock sensations and akathisia—suggested a broader, more complex withdrawal syndrome. The convergence of symptoms from two pharmacological classes posed a diagnostic challenge that clinicians could easily misattribute to opioid withdrawal, along with potential symptoms of depression. Therefore, in this context, the possibility of not identifying the withdrawal from antidepressants is very high, with consequential problematic effects.

Review of systems summary

Mr. M presents with a constellation of symptoms that align closely with withdrawal syndromes, both opioid and SSRI-related. He reports persistent fatigue and notes possible fluctuations in weight, though there is no indication of an underlying systemic illness. He describes vague chest discomfort, which appears to be linked to heightened anxiety during withdrawal. Also, the mild shortness of breath seems to be due to anxiety than to any primary pulmonary issue.

Gastrointestinal complaints are consistent with those already documented in the context of withdrawal, with no new findings. Neurologically, Mr. M shows no focal deficits, and his symptoms are in keeping with SSRI discontinuation. Musculoskeletal complaints include diffuse muscle and joint pain, which seem to stem from a combination of chronic pain syndrome and the acute effects of opioid withdrawal. Psychiatrically, he exhibits emotional lability, anxiety, and irritability - hallmarks of both opioid and antidepressant withdrawal processes. (Table 1)

Table 1 Summary of findings

Category	Findings
General observations	Fatigue and weight changes without systemic illness
Cardiovascular findings	Non-specific chest discomfort, likely anxiety-related
Respiratory assessment	Mild dyspnea, attributed to anxiety
Gastrointestinal evaluation	No new findings beyond withdrawal-related symptoms
Neurological examination	No focal deficits; consistent with SSRI withdrawal
Musculoskeletal concerns	Diffuse pain is likely due to chronic pain and opioid withdrawal
Psychiatric evaluation	Emotional instability, anxiety, and irritability linked to withdrawal

Laboratory and toxicology findings

A comprehensive panel of laboratory and toxicology tests was conducted to support the clinical impression and exclude alternative medical explanations for Mr. M's presentation. His complete blood count (CBC) revealed normal red and white blood cells and platelets, effectively ruling out infection, anemia, or hematologic abnormalities. The comprehensive metabolic panel (CMP) showed normal liver and kidney function, indicating that his organs are functioning well and are capable of metabolizing and clearing medications appropriately.

Urinalysis was unremarkable, with no evidence of infection, renal impairment, or glycosuria. The urine drug screen provided critical diagnostic clarity: it detected methadone metabolites (EDDP) at a threshold of 100 ng/mL, confirming recent methadone use and supporting the clinical suspicion of opioid withdrawal.

Additionally, trace amounts of escitalopram metabolites (S-desmethyl citalopram) were present, consistent with recent discontinuation and indicative of SSRI withdrawal.

To rule out endocrine contributors to his symptoms, thyroid function tests were performed, which revealed normal results, including appropriate levels of TSH, T3, and T4. Additionally, the toxicology screen showed no other substances, ruling out any potential confounding drug effects.

Taken together, these findings strongly support a diagnosis of mixed withdrawal syndrome, involving both opioid and SSRI discontinuation. The absence of other medical or psychiatric causes, combined with the timing of medication cessation, underscores the importance of recognizing the complex symptomatology that can arise when multiple psychotropic and opioid agents are tapered or stopped concurrently. (Table 2)

Table 2 Salient summary of key findings

Test	Findings
CBC	Normal – no infection or hematologic abnormalities.
CMP	Normal liver and kidney function – adequate drug metabolism and clearance.
Urinalysis	Normal – no infection, renal issues, or glycosuria.
Urine drug screen	Methadone metabolites (EDPP): detected – confirms recent opioid use.
	Escitalopram metabolites: trace – consistent with recent SSRI discontinuation.
Thyroid function tests	Normal – rules out thyroid related mood or energy disturbances.
Other substances	None detected – no confounding drug effects.

Utilization of assessment tools for diagnosing mixed withdrawal states: clinical vignette

Diagnosing complex withdrawal states—especially when symptoms overlap with psychiatric and medical conditions—requires a structured, multidimensional approach. With the patient who will be identified as Mr. M, the clinical team employed a comprehensive battery of validated assessment tools to clarify the nature of his symptoms and confirm a diagnosis of mixed withdrawal involving both methadone and escitalopram.

To begin, standardized instruments were used to quantify and differentiate symptom domains. The Clinical Opiate Withdrawal Scale (COWS) provided an objective measure of opioid withdrawal severity, while the Discriminatory Antidepressant Withdrawal Symptoms Scale (DAWSS) helped isolate symptoms specific to SSRI discontinuation. To assess overlapping psychiatric features, the team administered the Generalized Anxiety Disorder-7 (GAD-7)[20] and the Patient Health Questionnaire-9 (PHQ-9),[21] both of which are widely used for evaluating anxiety and depression, respectively. The Amphetamine Withdrawal Scale[22] was included to rule out stimulant-related symptoms, and the Numerical Rating Scale (NRS)[23] was used to track subjective pain intensity, which had increased significantly during the withdrawal process.

Beyond symptom quantification, the team conducted a thorough differential diagnosis to exclude alternative explanations. Substance use disorders, such as amphetamine or alcohol withdrawal, were ruled out based on clinical presentation, routine liver function tests, and a negative Alcohol Use Disorders Identification Test (AUDIT) score.[24] Medical conditions, including chronic pain and neurological disorders, were also considered. Mr. M's chronic pain likely intensified during withdrawal, there were no signs of neurological disease. Symptoms such as tingling, dizziness, and akathisia were more consistent with SSRI withdrawal, in the context of recent escitalopram discontinuation.

A focused mental health evaluation revealed that Mr. M was anxious, restless, and emotionally labile, yet remained oriented and coherent. Sleep disturbances were prominent and contributed to his distress. A detailed clinical interview and application of DSM-5 criteria[25] ruled out primary mood or anxiety disorders. Mr. M had no significant psychiatric history during periods of abstinence, reinforcing the conclusion that his symptoms were withdrawal-related rather than indicative of a psychiatric diagnosis.

The integration of these findings confirmed a mixed withdrawal syndrome. His COWS score of 20 indicated moderate opioid withdrawal, while a DAWSS score of 18 reflected significant SSRI withdrawal. His GAD-7 score of 14 and PHQ-9 score of 12 pointed to moderate anxiety and moderately severe depression, respectively—both likely withdrawal-induced. His pain score notably increased from 6 to 9, indicating a significant rise in discomfort and the physical toll of withdrawal symptoms.

This case underscores the value of structured assessment tools and a methodical diagnostic process in identifying complex withdrawal presentations. Mr. M's experience illustrates how overlapping withdrawal syndromes can mimic primary psychiatric or medical conditions, and how careful evaluation can guide more accurate diagnosis and targeted treatment planning. (Table 3)

Table 3 Summary of key findings

Assessment tools used	Score	Interpretation
COWS	20	Moderate opioid withdrawal
DAWSS	18	Significant SSRI withdrawal
GAD-7	14	Moderate anxiety
PHQ-9	12	Moderate depression
NRS pain	Increased from 6 to 9	Heightened pain sensitivity
Amphetamine withdrawal scale	N/A	Used to rule out stimulant-related symptoms
Alternative diagnoses ruled out	**Findings**	

Table 3 Continued....

Substance use disorders	No evidence of amphetamine or alcohol withdrawal
Medical condition	No signs of neurological disease: chronic pain likely exacerbated by withdrawal
Primary psychiatric disorders	Ruled out via DSM-5 criteria and clinical history

In conclusion, the findings support a diagnosis of mixed withdrawal syndrome due to recent discontinuation of methadone and escitalopram.

The interplay of liver metabolism, receptor kinetics, and kindling in antidepressant and opioid withdrawal

Withdrawal from psychiatric medications, such as selective serotonin reuptake inhibitors (SSRIs) like escitalopram and opioids like methadone, involves a complex interaction between pharmacokinetics - how the body processes these drugs, and pharmacodynamics - how these drugs affect the body. Two biological mechanisms play a significant role in this context: hepatic metabolism and receptor dissociation kinetics. These factors influence both the onset and severity of withdrawal symptoms and affect the risk of kindling. Kindling refers to a process where repeated withdrawal episodes result in progressively more severe and destabilizing symptoms.[26]

Liver metabolism and withdrawal dynamics

The liver metabolizes both escitalopram and methadone via the cytochrome P450 (CYP450) enzymes, though different metabolic pathways:

(i) CYP2C19, CYP2D6, and CYP3A4 primarily metabolizes escitalopram. Genetic polymorphisms in these enzymes can lead to significant interindividual variability in drug clearance. For example, individuals with the CYP2C19*17 allele may metabolize escitalopram more rapidly, while poor metabolizers may accumulate higher plasma levels, increasing the risk of abrupt and intense withdrawal upon discontinuation.[27]

(ii)Methadone is metabolized mainly by CYP3A4, CYP2B6, and CYP2D6. Its metabolism is highly variable and influenced by genetic factors, liver function, and drug-drug interactions. This variability can result in prolonged half-lives or rapid clearance, affecting withdrawal timing and severity.[28]

Dissociation curve and receptor occupancy

The dissociation curve—how tightly and how long a drug binds to its receptor—plays a critical role in withdrawal dynamics:

(i) Escitalopram binds tightly to the serotonin transporter (SERT) and dissociates slowly, maintaining serotonergic tone even at low plasma levels. However, once the drug is discontinued, receptor occupancy can drop sharply, triggering acute withdrawal symptoms such as dizziness, irritability, and sensory disturbances.[29]

(ii) Methadone binds with high affinity to μ-opioid receptors and dissociates slowly, contributing to its long duration of action. Nevertheless, when plasma levels fall below a critical threshold, rapid receptor unbinding can precipitate intense opioid withdrawal, particularly in individuals with high tolerance.[30]

Kindling: Neurobiological sensitization in withdrawal

Kindling refers to the progressive intensification of withdrawal symptoms following repeated episodes of substance discontinuation or dose reduction. Initially described in seizure disorders, kindling is now recognized as a key factor in the worsening of withdrawal syndromes over time.[31]

Mechanisms of kindling may include:

(i) Glutamatergic hyperactivity: Repeated withdrawal may upregulate excitatory neurotransmission via NMDA receptors, increasing neural excitability.[31]

(ii) GABAergic downregulation: Chronic drug exposure suppresses inhibitory tone, and withdrawal unmasks this imbalance, contributing to anxiety, agitation, and seizures.

(iii) Neuroinflammation: Repeated withdrawal stress activates microglia and astrocytes, promoting inflammatory cascades that sensitize neural circuits.[32]

(iv) HPA axis dysregulation: Chronic withdrawal disrupts the hypothalamic-pituitary-adrenal axis, leading to heightened stress responses and emotional instability. (Table 4)

Table 4 Clinical considerations

Category	Details
Clinical manifestations	(i) Escalating symptom severity with each withdrawal episode (ii) Prolonged recovery periods (iii) Cross-sensitization between drug classes
Risk factors	(i) Multiple withdrawal attempts without adequate tapering (ii) Abrupt discontinuation of long-term medications (iii) Polypharmacy, especially involving CNS-active agents (iv) Underlying psychiatric or neurological conditions (v) Genetic predispositions affecting neuroplasticity and metabolism
Implications for clinical practice	(i) Emphasize slow, symptom-guided tapering (ii) Monitor for early signs of sensitization (iii) Educate patients to reduce fear-driven discontinuation

Iatrogenic comorbidity and behavioral toxicity

A critical but often overlooked factor in withdrawal and tapering is iatrogenic comorbidity - the adverse psychological and physiological effects induced by prior medical treatments, particularly psychotropic drugs.[33]

Key insights

(i) Behavioral toxicity: Psychotropic medications can cause affective disturbances, paradoxical reactions, tolerance, and post-withdrawal syndromes, often misinterpreted as treatment resistance.

(ii) Cascade iatrogenesis: One adverse effect can trigger a chain of medical and psychiatric complications, especially in long-term or polypharmacy contexts.

(iii) Clinical blind spots: Current psychiatric models often ignore iatrogenic factors, leading to misdiagnosis and ineffective treatment.

(iv) Systemic bias: Evidence-based guidelines may overstate drug benefits while underestimating risks, often influenced by pharmaceutical marketing.

Implications

(i) Withdrawal symptoms may reflect more profound iatrogenic alterations, not just neurochemical rebound.

(ii) If clinicians do not address iatrogenic factors, patients may experience poor long-term psychiatric outcomes.

(iii) A paradigm shift is needed—one that integrates biological, psychosocial, and iatrogenic dimensions of mental health.

Incorporating the aforementioned factors into the clinical process may present some challenges, yet doing so is crucial for recognizing their often-overlooked influence on patient outcomes. Including these elements in medical training and in continuing medical education provides clinicians with a valuable opportunity to deepen their understanding and effectively address their impact on clinical care and outcomes.

Preventing and managing mixed withdrawal and kindling

In individuals with histories of polypharmacy, discontinuation of both SSRIs and opioids can result in mixed withdrawal**,** where overlapping symptoms from different drug classes amplify one another. As stated, repeated or poorly managed withdrawal episodes can lead to kindling.

Strategies

(i) Staggered tapering: Prioritize tapering one medication at a time, starting with the one with the shorter half-life or more severe withdrawal profile.

(ii) Microtapering: Use micro dosing tapers to minimize psycho-neurological destabilization.

(iii) Alternate tapering: Pause tapering of one drug if complications arise and consider switching to tapering of another psychiatric medication.

(iv) Pharmacogenetic testing: Identify CYP450 polymorphisms to personalize tapering schedules.[34]

(v) Monitoring and flexibility: Be prepared to pause or reverse tapers if destabilization occurs.

(vi) Adjunctive support: Use psychological and lifestyle-based support during tapering of psychiatric medications. These may include:

a) Psychological interventions, including cognitive-behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), or supportive counseling, which can help individuals manage emotional and cognitive challenges during the tapering process.

b) Lifestyle modifications, such as maintaining regular physical activity, practicing good sleep hygiene, and establishing structured daily routines to support overall mental and physical well-being.

c) Nutritional support, such as omega-3 fatty acids, B-complex vitamins, and magnesium. While some individuals report benefits anecdotally, current scientific evidence supporting their effectiveness in easing withdrawal symptoms is limited and not yet conclusive.

d) Peer support or group therapy, offering shared experiences, emotional validation, and practical coping strategies from others undergoing similar transitions. (Table 5)

Table 5 Pharmacokinetic, pharmacodynamics, and iatrogenic factors in escitalopram and methadone withdrawal

Factor	Escitalopram (SSRI)	Methadone (Opioid)
Primary metabolic enzymes	CYP2C19, CYP2D6, CYP3A4	CYP3A4, CYP2B6, CYP2D6
Metabolic variability	High individual-to-individual variability due to genetic polymorphisms	High variability due to genetics, drug interactions, and liver function
Receptor target	Serotonin transporter (SERT)	μ-opioid receptor
Receptor binding affinity	High	High
Dissociation rate	Slow (sustains serotonergic tone at low plasma levels)	Slow (prolongs opioid effect)
Withdrawal onset	Delayed but abrupt once receptor occupancy drops	Delayed but intense once plasma levels fall below the threshold
Withdrawal symptoms	Dizziness, irritability, sensory disturbances	Cravings, anxiety, gastrointestinal distress, dysphoria
Kindling risk	Elevated with repeated discontinuation or abrupt tapering	Elevated with repeated detoxification or unmanaged tapering
Iatrogenic comorbidity	Behavioral toxicity, paradoxical effects, post-withdrawal syndromes, treatment resistance	Cascade iatrogenesis, misdiagnosis, poor long-term outcomes due to prior treatments
Clinical implication	Requires gradual tapering, especially in poor metabolizers; monitor for iatrogenic effects	Requires individualized tapering and awareness of prior treatment-induced vulnerabilities

Treatment plan for Mr. M

Several key clinical objectives guided the structured use of assessment tools in Mr. M's case:

(i) Accurate differentiation between withdrawal symptoms and primary psychiatric conditions

(ii) Prevention of misdiagnosis and inappropriate pharmacological interventions

(iii) Targeted management of withdrawal symptoms to support recovery

The combination of standardized scales and laboratory tests proved essential in confirming the diagnosis of mixed withdrawal. This diagnostic clarity enabled the clinical team to formulate a more precise and individualized treatment plan. Unfortunately, Mr. M disengaged from care before the full implementation of this plan. Despite receiving a clear explanation of his diagnosis, he did not remain in treatment long enough to benefit from the tailored interventions.

If Mr. M had stayed in care, his treatment plan would have aimed to stabilize the symptoms related to withdrawal from both methadone and escitalopram. His early departure could have been due to the physical discomfort caused by withdrawal and a feeling that the provider's approach did not align with his needs. Increased involvement from

peer specialists might have enhanced his engagement and adherence to the treatment plan.

Proposed treatment steps

1. **Reintroduction of methadone:** To stabilize opioid withdrawal, methadone should be reintroduced at a low dose and gradually titrated to a therapeutic level. This approach minimizes the risk of triggering a kindling effect, in which repeated withdrawal episodes lead to increasingly severe symptoms.[26] Erratic or repeated withdrawal from medications may contribute to a kindling-like effect, particularly in individuals with co-occurring mental health conditions, thereby increasing the risk of relapse and complicating the recovery process.[35]
2. **Reintroduction of escitalopram:** Escitalopram should be restarted cautiously at a low dose, with gradual titration. This strategy also helps prevent serotonergic destabilization and mitigates the risk of withdrawal-induced neuropsychiatric symptoms.[36] By judiciously reintroducing both methadone and escitalopram, the clinical team could reduce the likelihood of a double kindling effect**,** where withdrawal from two CNS-active agents amplifies neurobiological sensitization.

During this period, strong psychological support is essential to buffer distress and promote adherence.

3. **Monitoring methadone levels:** Regular monitoring of methadone serum levels - both peak and trough - is essential to ensure therapeutic stability. Weekly assessments are recommended during the initial stabilization phase, transitioning to bi-weekly once steady-state levels are achieved.[37]
4. **Monitoring escitalopram levels:** Therapeutic drug monitoring of escitalopram should also be conducted weekly at first, then bi-weekly. Pharmacogenomic testing can provide insights into Mr. M's metabolic profile (e.g., CYP2C19 and CYP2D6 polymorphisms), allowing for more precise dosing and minimizing adverse effects.[38]
5. **Use of serial daily withdrawal scales:** Incorporating daily withdrawal assessments using validated tools such as the Clinical Opiate Withdrawal Scale (COWS) and the Discriminatory Antidepressant Withdrawal Symptoms Scale (DAWSS) enables real-time treatment adjustments. This proactive approach enhances symptom management and supports individualized care.[4,19]
6. **Integration of peer specialists:** Peer specialists can play a transformative role in supporting individuals through withdrawal. Their lived experience fosters empathy, cultural sensitivity, and trust. Peer involvement helps bridge the gap between clinical care and patient experience by promoting self-determination and open communication with prescribers. Peer support has also been associated with improved self-esteem, resilience, and treatment retention.[39]
7. **Psychopharmacology within a psychosocial-cultural framework:** Effective withdrawal management must account for the sociocultural context in which individuals live. Cultural beliefs, identity, and community dynamics influence how patients perceive medications, engage with treatment, and experience withdrawal.[7]

These factors are not peripheral - they are central to the success of any intervention. Recovery-oriented approaches that are culturally attuned play a crucial role in building trust and maintaining patient engagement, especially among populations that psychiatric care has historically underserved.[40] Tohidian and Quek emphasize that integrating culturally relevant practices into therapeutic relationships enhances the effectiveness of interventions and supports recovery. When interventions are designed with specific cultural contexts in mind, clinicians are better equipped to connect with patients, fostering a strong therapeutic alliance that is vital for sustaining long-term engagement. For example, in community-based mental health care, strategies that consider individuals' cultural backgrounds have been shown to improve access to services and lead to better patient outcomes.[41]

In addition, considering community dynamics can improve continuity of care and optimize the transition from withdrawal management to ongoing post-treatment support. Liang et al. highlight the importance of providing alcohol-relapse prevention interventions immediately after withdrawal management, showing how an understanding of community structures and resources enhances the effectiveness of these efforts.[42] Similarly, incorporating culturally informed practices into withdrawal management not only improves immediate health outcomes but also supports long-term recovery and stability after treatment.[43]

Vignettes on mixed withdrawal: Integrating ethno cultural aspects in withdrawal management

Understanding the multifaceted challenges of discontinuing medications such as escitalopram and methadone necessitates a comprehensive framework that integrates pharmacological, genetic, psychosocial, and cultural perspectives. While the initial clinical case provided a foundational exploration of these complexities, it also revealed critical gaps in addressing the broader contextual and individualized factors that influence withdrawal trajectories. To address these gaps, the following two theoretically informed clinical vignettes are presented. These vignettes are not merely illustrative but are strategically constructed to deepen the analysis of antidepressant withdrawal within the context of Medication-Assisted Treatment (MAT).[44,45] Specifically, they highlight the interplay between biological predispositions, cultural narratives, and the role of peer-led and community-based interventions. By doing so, they aim to enrich the clinical discourse and support the development of more nuanced, person-centered approaches to withdrawal management.

Vignette 1: fast metabolizer experience in a traditionally slow-metabolizing population

Patient background

Ms. P., a 29-year-old woman of East Asian descent, was undergoing treatment for generalized anxiety disorder with escitalopram and receiving methadone maintenance therapy for opioid use disorder. At some point in her treatment, she began experiencing destabilizing withdrawal symptoms, despite strict adherence to her prescribed regimen. Pharmacogenomic testing revealed that Ms. P possessed rare gene variants in the CYP2C19 and CYP3A4 enzymes - key pathways responsible for the metabolism of both escitalopram and methadone. This finding was particularly notable given that individuals of East Asian ancestry are more commonly associated with slower hepatic metabolism due to the prevalence of reduced-function alleles in these enzymes.[46]

This case challenges the assumption that ethnically associated metabolic profiles can be reliably generalized to individuals. Ms. P's experience underscores the importance of individualized approaches and pharmacogenomic testing, particularly in populations where group-level data may shape clinical expectations. Her rapid

metabolism caused significant fluctuations in drug plasma levels, which in turn contributed to withdrawal symptoms that doctors initially misattributed to other factors like non-adherence to treatment.[47]

Cultural interpretation played a pivotal role in Ms. P's response to her symptoms. She initially framed her experience through a spiritual lens, attributing her distress to a disruption in internal balance rather than to pharmacologic withdrawal. This spiritual belief delayed her return to care and highlighted the need for culturally competent communication in clinical settings. Ultimately, it was the involvement of a culturally matched peer support specialist that facilitated her re-engagement with treatment, demonstrating the value of peer-informed, culturally responsive care in withdrawal management.

Pharmacokinetic implications

The CYP2C19 and CYP3A4 enzymes primarily govern the pharmacokinetic profile of escitalopram. Metabolism of this drug more rapid in individuals with increased enzymatic activity, such as Ms. P, resulting in lower-than-expected plasma concentrations. This can lead to a paradoxical situation in which the patient experiences symptoms of anxiety and withdrawal despite being adherent to the prescribed dose.[48] In Ms. P's case, the rapid clearance of escitalopram likely contributed to sub therapeutic exposure, undermining its intended anxiolytic effects.

Methadone, a key treatment for opioid use disorder, is metabolized through a complex pathway involving CYP3A4, CYP2B6, and CYP2D6 enzymes. Ms. P's increased CYP3A4 activity likely sped up methadone clearance, diminishing its effectiveness in controlling opioid cravings and withdrawal symptoms.[49] This pharmacokinetic mismatch placed her at increased risk of relapse and destabilization, particularly during periods of stress or dietary fluctuation.

Administered concurrently, the overlapping metabolic pathways of both medications, especially through CYP3A4, can lead to competitive metabolism and further complicate dosing strategies.[50] In Ms. P's case, the combination of fast metabolism and shared enzymatic pathways necessitated frequent dose adjustments and close clinical monitoring to maintain therapeutic stability.

Restarting and monitoring treatment

In light of Ms. P's fast metabolizer status and her recent withdrawal symptoms, her care team implemented a revised treatment plan that prioritized safety, stabilization, and individualized dosing. Methadone was reintroduced at a conservative starting dose, with gradual titration based on clinical response and plasma level monitoring. This approach aimed to avoid both under dosing, which could precipitate withdrawal, and overdosing, which could lead to sedation or toxicity.

The team restarted escitalopram at a low dose, paying close attention to the phenomenon of kindling which can lead to increasingly severe symptoms. They also implemented regular monitoring of methadone's peak and trough levels to guide dosing decisions and maintain consistent therapeutic exposure. This pharmacokinetic monitoring allowed for a personalized approach to managing Ms. P.'s unique metabolic profile, reducing the risk of further destabilization.[51]

Cultural dietary influences on drug metabolism

An often-overlooked factor in pharmacokinetics is the influence of diet, particularly in culturally specific eating patterns. Ms. P's traditional East Asian diet included a high intake of cruciferous vegetables such as bok choy, napa cabbage, and Chinese broccoli. These foods are rich in glucosinolates and other compounds known to induce hepatic enzymes, particularly CYP1A2 and potentially CYP3A4.[52] In a fast metabolizer like Ms. P, this dietary pattern may have further accelerated drug metabolism, compounding the challenges of maintaining therapeutic drug levels.

Understanding the interaction between diet and drug metabolism is essential in culturally competent care. For example, while cruciferous vegetables may enhance metabolism, other common dietary components such as grapefruit, green tea, and soy products can inhibit key enzymes like CYP3A4 and CYP1A2.[53] Depending on the individual's metabolic profile and dietary consistency, these interactions can either mitigate or exacerbate withdrawal symptoms.

Counseling strategies

Effective counseling in this context must be both personalized and culturally sensitive. The first step involves providing Ms. P with clear, accessible education about her pharmacogenomic profile. Explaining that her body processes medications more quickly than average helped normalize her experience and reduce feelings of failure or self-blame. This biological framing also empowered her to participate more actively in her treatment planning.[54]

Dietary counseling was another critical component. A registered dietitian with expertise in East Asian dietary patterns collaborated with the care team to help Ms. P understand how her food choices could influence medication levels.[55] Rather than recommending dietary elimination, the team emphasized moderation and consistency, aiming to stabilize enzyme activity and reduce fluctuations in drug metabolism.[56]

The team approached withdrawal and medication planning by focusing on gradual titration, conducting frequent clinical check-ins, and utilizing symptom-tracking tools. These tools allowed Ms. P. and her providers to identify patterns in mood, diet, and medication responses, enabling timely adjustments and preventing the escalation of symptoms.[57]

Cultural sensitivity extended beyond the clinical encounter. The care team acknowledged the central role of family and cultural values in Ms. P's healing process. With her consent, family members were invited to participate in educational sessions, helping to reduce stigma and foster a supportive environment.[58] Culturally appropriate metaphors and analogies were used to explain complex treatment concepts, enhancing comprehension and trust.[59]

Finally, peer support played a transformative role in Ms. P's recovery. A culturally matched peer specialist provided validation, shared lived experiences, and helped normalize the challenges of withdrawal.[60]

Participation in culturally respectful support groups further reinforced her sense of belonging and resilience.[61]

Psychological aspects of treatment

The psychological dimensions of withdrawal management are often underappreciated, yet they play a critical role in treatment adherence and recovery outcomes. The psychological toll can be profound for individuals like Ms. P, whose fast metabolizer status complicates pharmacologic stability.[62]

One of the immediate challenges is therapeutic frustration. Ms. P may perceive that her medications are ineffective, despite strict adherence. This perception may be common among fast metabolizers, who often experience sub therapeutic drug levels due to accelerated hepatic clearance, particularly through enzymes such as CYP2C19 and CYP3A4.[63]

Cultural expectations further shape Ms. P's psychological experience. In many East Asian cultures, emotional restraint and

prioritizing family harmony are deeply embedded values.[64] These norms may discourage open expression of psychological distress, leading to internalized anxiety, shame, and somatic presentations of emotional suffering.[65]

The stigma surrounding mental health and substance use disorders in Ms. P's community adds another layer of psychological burden. In collectivist societies, where individual behavior is often viewed through the lens of family reputation, seeking psychiatric or addiction treatment may be perceived as dishonorable.[66]

Additionally, Ms. P may experience identity conflict as she navigates between traditional cultural beliefs and the Western biomedical model. If her family favors herbal remedies, acupuncture, or spiritual healing, she may feel torn between honoring her cultural heritage and complying with medical advice.[67]

Role of culturally sensitive peer support specialists

In this context, integrating a culturally sensitive peer support specialist can be transformative. Individuals who share the patient's lived experience and cultural background effectively bridge the gap between clinical care and cultural understanding.[68]

A peer specialist can help validate Ms. P's experience by explaining that her fast metabolism is a biological trait, not a personal failing.[69] This reframing is essential for reducing self-blame and restoring a sense of agency, particularly in patients who have internalized feelings of inadequacy due to perceived treatment failure.[70]

Moreover, peer specialists can act as cultural mediators, facilitating respectful and effective communication between Ms. P and her healthcare providers.[71] They can help translate complex medical concepts into culturally resonant language, using metaphors or analogies that align with traditional beliefs.[72]

Peer support also plays a critical role in normalizing Ms. P's experience. The peer specialist can reduce feelings of isolation and stigma by sharing stories from others in her community who have faced similar challenges.[73]

Peer specialists offer emotional support and practical assistance. They can help Ms. P track her symptoms, monitor dietary influences, and communicate effectively with her care team.[74]

Finally, peer support can empower Ms. P to make informed dietary choices without feeling culturally alienated. Rather than framing traditional foods as problematic, the peer specialist can help her understand how certain ingredients may influence drug metabolism and how to maintain consistency in her diet to support treatment goals.[75]

Vignette 2: slow metabolizer experience in a traditionally fast-metabolizing population

Patient background

A healthcare provider has prescribed escitalopram to Mr. D, a 35-year-old Native American man, for major depressive disorder, and methadone for his opioid use disorder. Pharmacogenomic testing revealed that Mr. D is a slow metabolizer, carrying reduced-function alleles in CYP2C19 and CYP3A4 enzymes critical to the metabolism of his prescribed medications. This metabolic profile may be considered atypical for his population group, where faster metabolism is commonly observed. The implications of this finding are clinically significant, as Mr. D's slow metabolism increases his risk of drug accumulation, adverse effects, and treatment disengagement.[76]

Pharmacokinetic implications

Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by CYP2C19 and CYP3A4.[77] In slow metabolizers like Mr. D, reduced enzymatic activity leads to prolonged drug exposure, even at standard doses. This increases the risk of side effects such as fatigue, gastrointestinal discomfort, and emotional blunting. Mr. D may experience supratherapeutic plasma levels without dose adjustments, which can compromise safety and adherence.[28]

Methadone, a long-acting opioid agonist used in medication-assisted treatment (MAT), is metabolized by CYP3A4, CYP2B6, and CYP2D6.[78] In Mr. D's case, slowed methadone metabolism results in drug accumulation, elevating the risk of sedation, QT interval prolongation, and respiratory depression.[79] These risks necessitate a conservative dosing strategy and extended intervals between titrations.

The combined pharmacokinetic burden of both medications, each dependent on overlapping metabolic pathways, further amplifies the risk of drug-drug interactions and toxicity.[80] Mr. D's profile underscores the need for individualized dosing and vigilant monitoring to ensure therapeutic efficacy without compromising safety.

Restarting and monitoring treatment

Following a recent treatment interruption, Mr. D's care team opted to restart methadone at a low dose, with gradual titration to avoid accumulation and toxicity. The healthcare team cautiously reintroduced escitalopram, starting at a reduced dose to minimize side effects and prevent kindling, a phenomenon in which repeated withdrawal episodes lead to heightened sensitivity and increased symptom severity.[81]

To ensure safety and optimize therapeutic outcomes, regular monitoring of methadone's peak and trough plasma levels was implemented. This approach allows for early detection of drug accumulation or under dosing and supports precise, individualized titration. In slow metabolizers like Mr. D, even small dose changes can have significant clinical effects, making pharmacokinetic surveillance essential.[82]

Cultural dietary influences on drug metabolism

Mr. D's traditional diet includes culturally significant foods such as blue corn, mutton, juniper ash, and herbal teas. While most of these foods are neutral with respect to CYP enzyme activity, certain ceremonial herbal infusions, such as sage or bear root, may inhibit CYP3A4, further slowing methadone metabolism.[83] Though often overlooked, these interactions can have meaningful clinical consequences in individuals with already reduced metabolic capacity.

Exploring Mr. D's dietary and ceremonial practices with cultural humility is essential to supporting his treatment. Rather than discouraging traditional practices, clinicians should aim to identify potential interactions and adjust treatment accordingly. This approach fosters trust and ensures that care is safe and culturally congruent.[84]

Psychological aspects of treatment

Mr. D's psychological experience during withdrawal management is shaped by a constellation of intersecting factors, each of which must be understood within the broader context of his cultural identity, historical background, and pharmacogenomic profile.

One of the immediate challenges is medication sensitivity. As a slow metabolizer of both escitalopram and methadone, Mr. D is more

likely to experience side effects such as sedation, gastrointestinal discomfort, and emotional blunting, even at standard or reduced doses. These adverse effects can be distressing and may lead to early treatment discontinuation, particularly if not adequately explained or anticipated. Without a clear understanding of the biological basis for these reactions, Mr. D may interpret them as signs that the treatment is harmful or ineffective, fostering mistrust in the medical system.[85]

Cultural identity also plays a central role in shaping Mr. D's engagement with care. For many Native American individuals, healing is a holistic process encompassing spiritual, communal, and environmental dimensions. Patients may feel alienated or disrespected when healthcare providers present Western medical approaches as the only option, without acknowledging or allowing consideration of traditional practices. Mr. D may experience internal conflict if he perceives that his cultural values are being dismissed or medicalized, which can undermine therapeutic alliance and adherence.[86]

The impact of historical trauma is another consideration to keep in mind. Native American communities have endured generations of systemic marginalization, forced assimilation, and medical exploitation. This legacy contributes to a well-documented mistrust of healthcare institutions, which may manifest in Mr. D. as guardedness, reluctance to disclose symptoms, or skepticism toward pharmacologic interventions. Providers must approach such responses not as resistance, but as protective adaptations rooted in collective experiences.[87]

Finally, community expectations may influence Mr. D's willingness to engage in mental health or addiction treatment. In many Indigenous communities, there is a strong cultural emphasis on resilience, self-reliance, and stoicism. These values, while protective in some contexts, may discourage open discussion of emotional distress or substance use. Mr. D may feel pressure to "tough it out" or avoid appearing vulnerable, which can delay seeking help and complicate recovery.[88]

Role of culturally sensitive peer support specialists

In this context, the involvement of a culturally sensitive peer support specialist is not merely beneficial—it is essential. Peer specialists who share Mr. D.'s cultural background and lived experience can serve as trusted guides, helping to bridge the gap between traditional healing and biomedical care.[89]

First, the peer specialist can help validate Mr. D's experience as a slow metabolizer, explaining in accessible terms how his genetic profile affects medication processing and side effect burden. This biological framing can reduce self-blame and foster a sense of empowerment, particularly when paired with reassurance that these challenges are manageable with appropriate adjustments.[90]

Second, peer support can facilitate respectful dialogue between Mr. D and his care team. By advocating for the inclusion of traditional practices and helping providers understand their cultural significance, the peer specialist ensures that Mr. D's identity is honored rather than marginalized.[91]

Third, the peer specialist can normalize Mr. D's experience by sharing stories of others who have successfully balanced cultural identity with recovery. These narratives can reduce feelings of isolation and stigma, reinforcing that healing does not require abandoning one's heritage.[92]

In addition to emotional support, peer specialists provide practical assistance. They can help Mr. D track side effects, monitor for signs of drug accumulation, and communicate concerns to his providers. This support is particularly valuable in slow metabolism, where small dose changes can have significant clinical effects.[93]

Finally, peer support can empower Mr. D to make informed decisions about using herbal remedies and ceremonial substances. Rather than discouraging these practices, the peer specialist can help Mr. D understand potential interactions and collaborate with his care team to ensure safety without cultural disruption.[94]

Conclusion

Emphasizing a culturally attuned recovery approach to withdrawal practices

This article has explored the multifaceted nature of withdrawal from psychiatric medications and opioids, emphasizing the need for a comprehensive, culturally responsive approach to care. Through the clinical case of Mr. M, we examined the diagnostic and therapeutic challenges of mixed withdrawal states, highlighting the importance of structured assessment tools, pharmacogenomic insights, and individualized treatment planning.

However, Mr. M's case highlighted the limitations of relying solely on a clinical framework, especially when sociocultural factors are not adequately considered. To build on this foundation, we introduced two additional vignettes. These vignettes provide complementary perspectives that enhance our understanding of withdrawal by examining cultural identity, community context, and metabolic variability.

These three narratives form a cohesive and global view of withdrawal management. Mr. M's case underscores the clinical and diagnostic rigor required to identify and treat mixed withdrawal states. Ms. P's experience illustrates how cultural stigma, familial expectations, and language barriers can shape treatment engagement and symptom expression. Mr. D's story highlights the critical role of pharmacogenomics and the need for culturally competent care in medication tapering, particularly among ethnically diverse populations.

By integrating these diverse yet interconnected experiences, this article advocates for a contextualized withdrawal care model that recognizes the interplay between biology, culture, and lived experience. Such a model must:

(i) Accurately differentiate withdrawal symptoms from primary psychiatric conditions to avoid misdiagnosis and inappropriate treatment.

(ii) Incorporate pharmacogenomic data to tailor medication regimens based on individual metabolic profiles.

(iii) Respect and integrate cultural beliefs and values that influence how individuals perceive medications and engage with care.

(iv) Utilize peer support specialists to bridge the gap between clinical protocols and patient realities, fostering trust, empowerment, and sustained engagement.

A culturally sensitive recovery framework enhances treatment adherence, aligns interventions with patients' values, and mitigates the risk of exacerbated withdrawal symptoms. It also promotes therapeutic alliance and reduces stigma, especially in cases involving poly-pharmacy, co-occurring disorders, and marginalized populations.

To improve outcomes for individuals experiencing withdrawal, healthcare providers must shift their clinical practices. They need training to recognize and respond to the sociocultural aspects of

withdrawal, moving beyond mere symptom management to adopt a more inclusive, recovery-oriented model of care. By making this shift, we can create more humane, effective, and empowering treatment environments that support individuals in managing withdrawal and reclaiming their agency and well-being on their recovery journeys.

Acknowledgments

None.

Funding

None.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Davis MA, Lin LA, Liu H, et al. Prescription opioid use among adults with mental health disorders in the United States. *J Am Board Fam Med*. 2017;30(4):407–417.
2. Scherrer JF, Salas J, Copeland LA, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. *Ann Fam Med*. 2016;14(1):54–62.
3. Substance Abuse and Mental Health Services Administration (SAMHSA). *Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health*. HHS Publication No. SMA 18-5068, NSDUH Series H-53.
4. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry*. 2019;6(6):538–546.
5. Redden SM, Tracy S, Shafer M. A metaphor analysis of recovering substance abusers' sensemaking of medication-assisted treatment. *Qual Health Res*. 2013;23(7):951–962.
6. Buckingham S, Frings D, Albery I. Group membership and social identity in addiction recovery. *Psychol Addict Behav*. 2013;27(4):1132–1140.
7. Kleinman A. *Patients and healers in the context of culture*. University of California Press; 1980.
8. Preiss A, Baumgartner P, Edlund MJ, et al. Using named entity recognition to identify substances used in the self-medication of opioid withdrawal: natural language processing study of Reddit data (preprint). *JMIR Form Res*. 2022;6(3):e33919.
9. Best D, Irving J, Collinson B, et al. Recovery networks and community connections: identifying connection needs and community linkage opportunities in early recovery populations. *Alcohol Treat Q*. 2016;35(1):2–15.
10. Ellis J, Han D, Mayo J, et al. The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment. *Br J Clin Pharmacol*. 2024;90(6):1408–1417.
11. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. *Psychother Psychosom*. 2015;84(2):72–81.
12. Breggin PR. *Psychiatric drug withdrawal: a guide for prescribers, therapists, patients and their families*. Springer Publishing Company; 2013.
13. Horowitz MA, Moncrieff J. Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles. *Curr Opin Psychiatry*. 2024;37(4):320–330.
14. Moncrieff J. *The bitterest pills: the troubling story of antipsychotic drugs*. Palgrave Macmillan; 2013.
15. Hall W. *Harm reduction guide to coming off psychiatric drugs*. The Icarus Project and Freedom Center; 2012.
16. Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. *Ther Adv Psychopharmacol*. 2021;11:2045125321991274.
17. Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. *Curr Drug Saf*. 2018;13(3):176–186.
18. Fava GA, Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. *J Clin Psychiatry*. 2019;80(6):19com12794.
19. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). *J Psychoactive Drugs*. 2003;35(2):253–259.
20. Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092–1097.
21. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–613.
22. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity, and factor structure of a measure. *Aust N Z J Psychiatry*. 1999;33(1):89–93.
23. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: a ratio measure? *Pain Pract*. 2003;3(4):310–316.
24. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. *Addiction*. 1993;88(6):791–804.
25. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th ed., text rev. Washington, DC: American Psychiatric Publishing; 2022.
26. Maviglia M, Cooeyate N, Hume D, et al. Kindling in psychopharmacology: unveiling an overlooked clinical challenge with significant implications. *J Psychol Clin Psychiatry*. 2024;15(5):282–290.
27. Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. *Clin Pharmacol Ther*. 2008;83(2):322–327.
28. Vazquez V, Gury C, Laqueille X. Methadone: from pharmacokinetic profile to clinical pharmacology. *Encephale*. 2006;32(4 Pt 1):478–486.
29. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. *Am J Psychiatry*. 2004;161(5):826–835.
30. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and future in mainstream medicine. *Ann N Y Acad Sci*. 2000;909:186–216.
31. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. *N Engl J Med*. 2003;348(18):1786–1795.
32. Crews FT, Vetreno RP. Mechanisms of neuroimmune gene induction in alcoholism. *Psychopharmacology (Berl)*. 2016;233(9):1543–1557.
33. Fava GA, Cosci F, Offidani E, et al. Behavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatment. *J Clin Psychopharmacol*. 2016;36(6):550–553.
34. Bousman CA, Stevenson JM, Hamilton SP, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2023;114(1):51–68.
35. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. *CNS Drugs*. 2013;27(7):545–572.

36. Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. *Psychother Psychosom*. 2020;89(5):283–306.

37. Chalabianloo F, Fadnes LT, Johansson KA, et al. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. *Basic Clin Pharmacol Toxicol*. 2024;134(3):333–344.

38. Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther*. 2017;102(1):37–44.

39. Mead S, Hilton D, Curtis L. Peer support: a theoretical perspective. *Psychiatr Rehabil J*. 2001;25(2):134–141.

40. Tohidian N, Quek K. Processes that inform multicultural supervision: a qualitative meta-analysis. *J Marital Fam Ther*. 2017;43(4):573–590.

41. Soroye MO, Oleribe OO, Taylor-Robinson SD. Community psychiatry care: an urgent need in Nigeria. *J Multidiscip Healthc*. 2021;14:1145–1148.

42. Liang Y, Roberts J, Conigrave K, et al. Alcohol relapse prevention health care after alcohol withdrawal in New South Wales prisons, Australia: a patient file review. *Drug Alcohol Rev*. 2023;42(7):1733–1743.

43. Fujita A, LaRosa A, Carter A. Treating withdrawal and pain in inpatients with opioid use disorder: a brief educational intervention for internal medicine residents. *MedEdPORTAL*. 2021;17:11123.

44. National Academies of Sciences, Engineering, and Medicine. *Medications for opioid use disorder save lives*. Washington, DC: The National Academies Press; 2019.

45. Maviglia M, Hume D, Cooeyate N. Peer support's role in helping individuals withdraw from psychiatric medications. *J Psychol Clin Psychiatry*. 2023;14(6):157–162.

46. Areesinpitak T, Kanjanawart S, Nakkam N, et al. Prevalence of CYP2C19, CYP3A4 and FMO3 genetic polymorphisms in healthy northeastern Thai volunteers. *ScienceAsia*. 2020;46(4):397–402.

47. Wollheim FR. Longitudinal analysis of pharmacogenomic variability in antidepressant metabolism and its relationship with treatment outcomes in major depressive disorder. *ICMERD Int J Med Sci*. 2024;5(1):1–6.

48. Aldrich SL, Poweleit EA, Prows CA, et al. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. *Front Pharmacol*. 2019;10:99.

49. Talal AH, Ding Y, Venuto CS, et al. Toward precision prescribing for methadone: determinants of methadone deposition. *PLoS One*. 2020;15(4):e0231467.

50. Volpe DA, Xu Y, Sahajwalla CG, et al. Methadone metabolism and drug-drug interactions: *in vitro* and *in vivo* literature review. *J Pharm Sci*. 2018;107(12):2983–2991.

51. Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2015;98(2):127–134.

52. Lampe JW, King IB, Li S, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. *Carcinogenesis*. 2000;21(6):1157–1162.

53. Harris RZ, Jang GR, Tsunoda SM. Dietary effects on drug metabolism and transport. *Clin Pharmacokinet*. 2003;42(13):1071–1088.

54. Strazewski L. *How pharmacogenomics enables precision approach to care*. American Medical Association. 2022.

55. Sun Z, Zheng Y. Metabolic diseases in the East Asian populations. *Nat Rev Gastroenterol Hepatol*. 2025;22(3):145–158.

56. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). *Drug Metabol Drug Interact*. 2004;20(4):195–217.

57. Boehringer Ingelheim. *Traditional symptom-tracking tools*. Connecting Psychiatry. 2025.

58. Corrigan PW, Lee EJ. Family-centered decision making for East Asian adults with mental illness. *Psychiatr Serv*. 2021;72(2):114–116.

59. Qin S, Corrigan P, Lee EJ. Family-centered decision making: a culturally responsive collaborative approach among Asians living in the United States. *Psychiatr Rehabil J*. 2024;47(2):94–105.

60. Jordan M, Hackett JT. Culturally responsive peer recovery. *Adv Addict Recovery*. 2019;18–22.

61. Cooper RE, Saunders KRK, Greenburgh A, et al. The effectiveness, implementation, and experiences of peer support approaches for mental health: a systematic umbrella review. *BMC Med*. 2024;22(1):72.

62. Au A. *Mental health in East Asia: cultural beliefs, social networks, and mental health experiences*. Routledge; 2023.

63. Mahajna M, Abu Fanne R, Berkovitch M, et al. Effect of CYP2C19 pharmacogenetic testing on predicting citalopram and escitalopram tolerability and efficacy: a retrospective, longitudinal cohort study. *Biomedicines*. 2023;11(12):3245.

64. National Alliance on Mental Illness. *Expectations and family pressure*. 2025.

65. Zheng S, Ishii K. *How do East Asians perceive and cope with psychological distress and stressful situations? A cultural-psychological perspective*. In: Mesquita B, Leu J, Gelfand MJ, eds. Handbook of Cultural Psychology. 2nd ed. Springer; 2025;365–376.

66. RRC Polytech. *Mental health stigma in East and South Asian communities*. 2024.

67. Chary A, Sargent C. Blending Western biomedicine with local healing practices. *AMA J Ethics*. 2016;18(7):691–697.

68. Kalibatseva Z, Leong FTL. A critical review of culturally sensitive treatments for depression: recommendations for intervention and research. *Psychol Serv*. 2014;11(4):433–450.

69. Mutschler C, Bellamy C, Davidson L, et al. Implementation of peer support in mental health services: a systematic review of the literature. *Psychol Serv*. 2022;19(2):360–374.

70. Smit D, Miguel C, Vrijsen JN, et al. The effectiveness of peer support for individuals with mental illness: systematic review and meta-analysis. *Psychol Med*. 2023;53(11):5332–5341.

71. Stefancic A, Bochicchio L, Tuda D. *Peer support for mental health*. In: Avery JD, ed. Peer Support in Medicine: A Quick Guide. Springer; 2021;31–48.

72. Magaña D. Cultural competence and metaphor in mental health-care interactions: a linguistic perspective. *Patient Educ Couns*. 2019;102(12):2192–2198.

73. Mental Health America. *Peer support: research and reports*. 2019.

74. Brinkley A, Volpe J. *Peer support services across the crisis continuum*. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2024.

75. Devries S. *To improve patients' dietary habits, keep cultural traditions in mind*. AMA News Wire. 2025.

76. Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. *Nat Rev Cardiol*. 2021;18(9):649–665.

77. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. *Clin Pharmacokinet*. 1997;32(Suppl 1):1–21.

Citation: Maviglia M, Cooeyate NJ, Hume D. Beyond tapering: understanding the biological, social, and recovery challenges of mixed withdrawal from psychiatric medications and opioids. *J Psychol Clin Psychiatry.* 2025;16(4):122–133. DOI: 10.15406/jpcpy.2025.16.00822

78. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. *Clin Pharmacokinet*. 2002;41(14):1153–1193.

79. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. *Pharmacotherapy*. 2003;23(6):802–805.

80. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism and bioactivation of methadone. *Clin Pharmacol Ther*. 2004;76(3):250–269.

81. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. *Am J Psychiatry*. 2008;165(3):342–351.

82. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. *Addiction*. 2000;95(12):1771–1783.

83. Gurley BJ, Gardner SF, Hubbard MA, et al. *In vivo* assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. *Clin Pharmacol Ther*. 2004;76(5):428–440.

84. Walters KL, Simoni JM, Evans-Campbell T. Substance use among American Indians and Alaska Natives: incorporating culture in an "indigenist" stress-coping paradigm. *Public Health Rep*. 2002;117(Suppl 1):S104–S117.

85. Perlis RH, Patrick A, Smoller JW, et al. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. *Neuropsychopharmacology*. 2009;34(10):2227–2236.

86. Gone JP. Redressing first nations historical trauma: theorizing mechanisms for indigenous culture as mental health treatment. *Transcult Psychiatry*. 2013;50(5):683–706.

87. Warne D, Frizzell LB. American Indian health policy: historical trends and contemporary issues. *Am J Public Health*. 2014;104(S3):S263–S267.

88. Walls ML, Whitbeck LB. The intergenerational effects of relocation policies on Indigenous families. *J Fam Issues*. 2012;33(9):1272–1293.

89. Areán PA, O'Connor S, Sherrill J. The promise and perils of using peers and other paraprofessionals as mental health service professionals. *JAMA Psychiatry*. 2025;82(2):107–108.

90. Oslin DW, Lynch KG, Shih MC, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the prime care randomized clinical trial. *JAMA*. 2022;328(2):151-161.

91. Hartmann WE, Gone JP. Incorporating traditional healing into an urban American Indian health organization: a case study of community member perspectives. *J Couns Psychol*. 2012;59(4):542–554.

92. Walters KL, Simoni JM. Reconceptualizing native women's health: an "Indigenist" stress-coping model. *Am J Public Health*. 2002;92(4):520–524.

93. Kini V, Ho PM. Interventions to improve medication adherence: a review. *JAMA*. 2018;320(23):2461–2473.

94. Christensen L, Damon S. Social determinants of health and response to disease associated with health outcomes of American Indian and Alaska Native patients. *JAMA Netw Open*. 2022;5(3):e224827.

Citation: Maviglia M, Cooeyate NJ, Hume D. Beyond tapering: understanding the biological, social, and recovery challenges of mixed withdrawal from psychiatric medications and opioids. *J Psychol Clin Psychiatry.* 2025;16(4):122–133. DOI: 10.15406/jpcpy.2025.16.00822